pemetrexed - EPARs for authorised medicinal products for human use - Alimta

FICHA FARMACOLÓGICA de pemetrexed . Contiene la Monografía en distintos idiomas (de la Unión Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Se recuerda que todas las informaciones científico-clínicas, así como técnicas propias de la producción, sólo se publican en idioma inglés. Cerasale. JUNIO 02, 2010.-

abrir aquí para acceder al documento EMA completo:
EPARs for authorised medicinal products for human use - Alimta

Active Substance
pemetrexed

International Nonproprietary Name or Common Name
pemetrexed

Pharmaco-therapeutic Group
Folic acid analogues

ATC Code
L01BA04

Therapeutic Indication
Malignant pleural mesothelioma:
Alimta in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer:
Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. First line treatment should be a platinum doublet with gemcitabine, paclitaxel or docetaxel.

Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.


Date of issue of Marketing Authorisation valid throughout the European Union
20 September 2004

Orphan medicinal product designation date
Not applicable


EPARs for authorised medicinal products for human use